Raptor’s Inhaled Levofloxacin MP-376, for Bronchiectasis and Other Conditions, Granted FDA’s QIDP Designation
News
California-based Raptor Pharmaceutical, a global biopharma that specializes in the development and commercialization of treatments for rare and debilitating diseases, recently announced that the U.S. FDA designated its inhaled levofloxacin treatment, MP-376, as a ... Read more